Importantly, analysis of the matched primary and metastatic ER+ breast tumor samples with the microfluidic gene expression assay suggested a generally high degree of concordance, with only six of 90 genes showing more than a 1.5 fold difference between matched primary and metastatic tissue and very high intra-patient correlation between primary and metastatic tumors. This evidence concerns the gene ESR1 and metastatic neoplasm.